Researchers and clinicians gathered in Barcelona this week for Advanced Technologies & Treatment for Diabetes (ATTD) 2026, where Dexcom used the conference as a platform to share several new findings and offer a preview of what is coming for its device lineup.

One of the more notable data points came from a registry study tracking type 2 diabetes patients who used the Dexcom G7 without insulin therapy for one year. According to data presented by Dexcom at ATTD 2026, those patients saw improvements in both blood sugar control and weight, adding to a growing conversation in the community about whether continuous glucose monitor (CGM) should be prescribed more broadly, even before insulin enters the picture.

Separate claims data painted an encouraging picture for type 1 patients. Both children and adults who used a Dexcom CGM had fewer emergency room visits and hospitalizations tied to diabetic ketoacidosis (DKA) compared to those who did not, suggesting that real-time alerts and continuous readings may play a meaningful role in preventing dangerous episodes.

A third study examined Smart Basal, a Dexcom G7 app feature aimed at patients beginning or adjusting basal insulin. The feasibility data indicated the tool performed safely and that patients reported feeling less burdened by their treatment process.

On the horizon, the company will introduced Dexcom Academy, a training platform for healthcare providers currently available in five countries, with further rollouts scheduled for later this year.

What are your thoughts on the data? Do you think CGM should be standard care for type 2 diabetes patients not yet on insulin? Leave your comments below.

Disclaimer: Diabetech content is not medical advice—it’s for educational purposes only. Always consult with a physician before making changes to your healthcare.